Published in Immunology on January 12, 2009
Chikungunya: a potentially emerging epidemic? PLoS Negl Trop Dis (2010) 2.05
A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis (2011) 1.45
Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines (2012) 1.44
Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother (2012) 0.95
Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination. Gene Ther (2011) 0.92
Zebrafish fin immune responses during high mortality infections with viral haemorrhagic septicemia rhabdovirus. A proteomic and transcriptomic approach. BMC Genomics (2010) 0.85
Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination. Vaccines (Basel) (2013) 0.82
DNA vaccines: a simple DNA sensing matter? Hum Vaccin Immunother (2013) 0.81
Co-Administration of Molecular Adjuvants Expressing NF-Kappa B Subunit p65/RelA or Type-1 Transactivator T-bet Enhance Antigen Specific DNA Vaccine-Induced Immunity. Vaccines (Basel) (2014) 0.80
High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines. Immunology (2014) 0.79
Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis. Clin Vaccine Immunol (2013) 0.78
Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem (2003) 8.34
Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev (2004) 6.08
A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science (1995) 4.64
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med (2008) 4.15
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis (1998) 3.60
The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol (2001) 3.43
Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol (2005) 3.05
HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 3.00
Structure of the HMG box motif in the B-domain of HMG1. EMBO J (1993) 2.84
NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood (2005) 2.15
Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol (2006) 2.14
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol (2005) 2.01
Generation or large numbers of immature and mature dendritic cells from rat bone marrow cultures. Eur J Immunol (1998) 1.92
Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine (2007) 1.88
CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest (1998) 1.87
Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine (2008) 1.87
Adjuvants: current status, clinical perspectives and future prospects. Immunol Today (1993) 1.70
Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine (2008) 1.67
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A (2007) 1.60
The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest (2008) 1.59
Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine (2007) 1.52
Structure of the A-domain of HMG1 and its interaction with DNA as studied by heteronuclear three- and four-dimensional NMR spectroscopy. Biochemistry (1995) 1.43
DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol (2000) 1.42
Developing DNA vaccines that call to dendritic cells. J Clin Invest (2004) 1.24
From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol (2006) 1.21
The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat Cell Biol (2006) 1.12
HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol (2004) 1.11
Virology. HIV gets by with a lot of help from human host. Science (2008) 1.06
Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine (2008) 1.04
Cytokines as adjuvants for improving anti-HIV responses. AIDS (2008) 1.03
HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation. Blood (2005) 1.02
Presentation of exogenous antigens by macrophages: analysis of major histocompatibility complex class I and II presentation and regulation by cytokines. Eur J Immunol (1994) 1.02
Duration of antigen expression in vivo following DNA immunization modifies the magnitude, contraction, and secondary responses of CD8+ T lymphocytes. J Immunol (2007) 0.98
Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine (2001) 0.97
Modifying professional antigen-presenting cells to enhance DNA vaccine potency. Methods Mol Med (2006) 0.96
Chemokines and TRANCE as genetic adjuvants for a DNA vaccine to rabies virus. Cell Immunol (2003) 0.87
HIV/AIDS. Treatment and prevention exchange vows at international conference. Science (2008) 0.84
DR5 activation of caspase-8 induces DC maturation and immune enhancement in vivo. Mol Ther (2007) 0.82
HIV/AIDS. The high cost of stolen funds. Science (2008) 0.77
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J Immunol (2002) 3.96
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol (2009) 3.37
Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature (2004) 2.90
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene (2003) 2.84
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther (2011) 2.29
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Chikungunya: a potentially emerging epidemic? PLoS Negl Trop Dis (2010) 2.05
Mechanisms by which SCN5A mutation N1325S causes cardiac arrhythmias and sudden death in vivo. Cardiovasc Res (2004) 2.04
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol (2005) 2.01
IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol (2011) 2.00
Temperature-modulated diversity of TRPV4 channel gating: activation by physical stresses and phorbol ester derivatives through protein kinase C-dependent and -independent pathways. J Biol Chem (2003) 1.97
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine (2007) 1.88
Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine (2008) 1.87
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Elevated telomere-telomere recombination in WRN-deficient, telomere dysfunctional cells promotes escape from senescence and engagement of the ALT pathway. Genes Dev (2005) 1.84
Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells. Mol Imaging Biol (2006) 1.84
Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One (2008) 1.80
Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol (2009) 1.77
Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75
Prevalence of endogenous CD34+ adipose stem cells predicts human fat graft retention in a xenograft model. Plast Reconstr Surg (2013) 1.70
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68
Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine (2008) 1.67
IL-17 family: cytokines, receptors and signaling. Cytokine (2013) 1.66
Randomized trial of group cognitive behavioral therapy compared with a pain education control for low-literacy rural people with chronic pain. Pain (2011) 1.65
Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A (2007) 1.60
A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes. J Immunol (2003) 1.59
SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol (2005) 1.57
Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Hum Gene Ther (2009) 1.57
ATF6alpha induces XBP1-independent expansion of the endoplasmic reticulum. J Cell Sci (2009) 1.57
HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine (2005) 1.56
Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine (2007) 1.52
An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. Vaccine (2012) 1.52
In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle (2011) 1.46
A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis (2011) 1.45
A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine (2005) 1.45
Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses (2005) 1.45
Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr). Cancer Biol Ther (2009) 1.44
Molecular genetic relationship of the 3' untranslated region among Thai dengue-3 virus, Bangkok isolates, during 1973-2000. DNA Cell Biol (2009) 1.42
Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther (2007) 1.40
DNA vaccines: developing new strategies to enhance immune responses. Immunol Res (2008) 1.36
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood (2013) 1.36
CTP: Phosphocholine cytidylyltransferase: paving the way from gene to membrane. J Biol Chem (2004) 1.35
An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity (2013) 1.35
HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem (2002) 1.31
Induction of inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway. Emerg Infect Dis (2002) 1.30
Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther (2010) 1.28
Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine (2008) 1.28
T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS (2002) 1.27
Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis (2011) 1.25
Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One (2012) 1.25
Developing DNA vaccines that call to dendritic cells. J Clin Invest (2004) 1.24
Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res (2014) 1.23
Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol (2008) 1.23
Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol (2008) 1.22
From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol (2006) 1.21
Functional characterization of MHC class II-restricted CD8+CD4- and CD8-CD4- T cell responses to infection in CD4-/- mice. J Immunol (2004) 1.19
Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol (2013) 1.19
Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma. J Allergy Clin Immunol (2005) 1.19
DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol (2006) 1.18
Role of proinflammatory cytokines and chemokines in chronic arthropathy in CHIKV infection. Viral Immunol (2011) 1.16
Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine (2008) 1.16
Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells. Nat Neurosci (2013) 1.16
Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J Virol (2008) 1.15
IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther (2010) 1.12